General
Preferred name
LEMBOREXANT
Synonyms
E-2006 ()
E2006 ()
Dayvigo ()
P&D ID
PD046945
CAS
1369764-02-2
Tags
available
drug
Approved by
PMDA
FDA
First approval
2019
2020
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Insomnia
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lemborexant is an orally active, dual orexin receptor antagonist (DORA) . (GtoPdb)
Compound Sets
11
ChEMBL Approved Drugs
CHEMBL3545367
ChEMBL Drugs
CHEMBL3545367
Drug Repurposing Hub
DrugBank
DB11951
DrugBank Approved Drugs
DB11951
DrugCentral
5360
DrugCentral Approved Drugs
5360
Guide to Pharmacology
9302
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL3545367
NCATS Inxight Approved Drugs
0K5743G68X
ReFrame library
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
410.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
3.74
TPSA
77.0
Fraction CSP3
0.27
Chiral centers
2.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
HCRTR1, HCRTR2
MOA
orexin receptor antagonist
Source data